LEPR and hyperinsulinism: The motivation of this study was to determine whether dapagliflozin could improve NASH db/db mice, which are leptin receptor deficient and have obesity, hyperglycemia, hyperinsulinemia, insulin resistance, and fatty liver, widely used as an animal model of NAFLD (Santhekadur et al., 2018).